## Case Report

Check for updates

# Bacteremia due to *Rahnella aquatilis* in a Patient with a Chemoport

1C Infection & Chemotherapy

#### Woo Joo Lee 💿 <sup>1</sup>, Youngpeck Song<sup>2</sup>, Sang Young Park<sup>3</sup>, and Mi Jeong Kim<sup>4</sup>

<sup>1</sup>Division of Infectious Disease, Department of Internal Medicine, Inseong Hallym Hospital, Incheon, Korea <sup>2</sup>Department of General surgery, Inseong Hallym Hospital, Incheon, Korea <sup>3</sup>Department of Internal Medicine, Inseong Hallym Hospital, Incheon, Korea <sup>4</sup>Division of Nephrology, Department of Internal Medicine, Inseong Hallym Hospital, Incheon, Korea

## ABSTRACT

*Rahnella aquatilis*, a saprophytic organism, is a member of the *Enterobacteriaceae* family. The natural habitat of this organism is fresh water, and it is rarely found in clinical specimens. Clinical conditions ascribed to this organism include bacteremia, respiratory infection, urinary tract infection, wound infection in an immunocompromised host, and infective endocarditis in patients with congenital heart diseases. Here, we report a case of bacteremia due to *R. aquatilis* in a woman with breast cancer who had received chemotherapy through a chemoport. To our knowledge, this is the second case of bacteremia caused by this organism in a patient with cancer in Korea.

Keywords: Rahnella aquatilis; Bacteremia; Chemoport; Chemotherapy; Breast cancer

# **INTRODUCTION**

*Rahnella aquatilis* exists in fresh water as an environmental organism and can cause infectious disease but the case of infection by this organism is uncommon [1]. Currently, little is known about the clinical manifestation, diagnosis and treatment for *R. aquatilis*. In Korea, there was only one report of bacteremia with this organism in hemodialysis patient which was published in 1997 [2]. This report describe a clinical course and treatment for a patient suffered from *R. aquatilis* bacteremia.

# **CASE REPORT**

A 58-year-old woman visited our hospital for breast cancer treatment. On 23 September, 2015, she underwent modified radical mastectomy of the left breast because of invasive ductal carcinoma. Chemotherapy with doxorubicin (60 mg/m<sup>2</sup> body surface area [BSA]) and cyclophosphamide (600 mg/m<sup>2</sup> BSA) was administered four times between 2 November, 2015, and 1 January, 2016. Starting from 25 January, 2016, the patient was administered paclitaxel infusion (80 mg/m<sup>2</sup> BSA) through a chemoport (B. Braun Celsite<sup>®</sup> Epoxy, France) which was inserted on that day via right subclavian vein for 12 cycles of infusion. On 12 April, 2016, the patient presented at our hospital for the tenth infusion of paclitaxel. At admission, her vital signs were stable, and the leukocyte count was 5,740/mm<sup>3</sup> (segmented neutrophils,

## OPEN ACCESS

**Received:** May 9, 2017 **Accepted:** May 17, 2017 **Published online:** Nov 1, 2018

#### Corresponding Author: Woo Joo Lee, MD

Division of Infectious Disease, Department of Internal Medicine, Inseong Hallym Hospital, 722, Jangje-ro, Gyeyang-gu, Incheon 21079, Korea.

Tel: +82-32-540-9124 Fax: +82-32-540-9283 E-mail: dawn728728@naver.com

**Copyright** © 2019 by The Korean Society of Infectious Diseases and Korean Society for Chemotherapy

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https:// creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

#### ORCID iDs

Woo Joo Lee https://orcid.org/0000-0002-4790-3560

**Conflict of Interest** No conflicts of interest.

61.1%). Before chemotherapy, saline was infused through the chemoport for hydration. Fourty minutes after the start of hydration, the patient complained of chills; 30 minutes later, she presented high fever (39°C) without any other symptoms except chills. The patient was administered an antipyretic, and two sets of blood samples were collected at different venous sites on the body. Blood cultures were performed using the VITEK 2 (bioMérieux, Marcy l'Etoile, France) automated system. On 13 April, 2016, the patient exhibited stable vital signs, without fever. She was then administered paclitaxel infusion as well as 1 g cefotiam every 12 hours as first empirical antibiotics. On 14 April, 2016, the fever had subsided, and the patient was discharged with a prescription for 100 mg cefixime two times daily for 7 days. On 20 April, 2016, the patient was admitted for the eleventh paclitaxel infusion, she did not exhibit any febrile events, probably because of medication with oral cefixime till admission. On 27 April, 2016, when she was admitted for the last dose of paclitaxel infusion, the leukocyte count was 2,620/mm<sup>3</sup> (segmented neutrophils, 40.3%). After paclitaxel infusion through the chemoport, the body temperature was noted to be 38.3°C, and the patient experienced chills. Two sets of peripheral blood samples were collected from different venous sites, and the patient was started on an empirical antibiotic regimen of 4.5 g piperacillin-tazobactam every 8 hours. On 28 April, 2016, the C-reactive protein levels had increased remarkably to 7.56 mg/dl. She strongly insisted on discharge, and the previous chart and laboratory data were reviewed before arriving at a decision on discharge medication. The cultures of the two sets of peripheral blood samples collected on 12 April, 2016, exhibited R. aquatilis in 4 bottles. Although the automated system could distinguish the organism, it could not perform antibiotic susceptibility tests. Therefore, antimicrobial susceptibility was evaluated by the disc diffusion method. The organism presented susceptibility to several antibiotics (Table 1). On the basis of these results, the patient was prescribed 200 mg oral cefixime two times daily as discharge medication. She visited the outpatient clinic on 4 May, 2016, for retrieving the results of the culture test of blood samples collected on 27 April, 2016, which again exhibited R. aquatilis. This organism was found in two sets (three bottles - two anaerobic bottles and one aerobic bottle) which was drawn from two different peripheral venous sites. On that day, blood samples were collected from both the chemoport and the peripheral vein for evaluating the clearance of bacteremia. Transthoracic echocardiography were done to find out if there's any sign of infective endocarditis because two serial collections of blood culture revealed bacteremia with the same organism, R. aquatilis. No evidence of infective endocarditis was observed. The oral cefixime regimen was changed to 500 mg oral ciprofloxacin two times daily for two days. The chemoport was removed on 23 May, 2016, and swabbed for culture

C Infection & Chemotherapy

Antibiotics	Date/Sensitivity					
	12 April, 2016			27 April, 2016		
	Result	Range	R/S	Result	Range	R/S
Amikacin	26	14~17	S	30	14~17	S
Amoxicillin + clavulanic acid	24	13~18	S	29	13~18	S
Aztreonam	30	15~22	S	35	15~22	S
Cefepime	33	14~18	S	35	14~18	S
Cefotaxime	26	14~23	S	31	14~23	S
Ciprofloxacin	31	15~21	S	28	15~21	S
Gentamicin	24	12~15	S	28	12~15	S
Imipenem	35	19~23	S	33	19~23	S
Tetracycline	21	11~15	S	23	11~15	S
Ampicillin	9	13~17	R	16	13~17	1
Cefuroxime	13	14~18	R	21	14~18	S
Cephalotin	10	14~18	R	16	14~18	I

R, resistant; S, sensitive; I, intermediate.

#### Bacteremia due to R. aquatilis in a Patient with a Chemoport




Figure 1. Clinical picture of Rahnella aquatilis bacteremia patient.

TZP, piperacillin-tazobactam; pphv, peripheral venous blood; CRP, C-reactive protein; N/A, not available.


samples. The results of blood culture via chemoport performed on 28 April, 2016, and chemoport tip culture performed on 23 May, 2016, were negative. Throughout this event, sputum and urine samples were also subjected to culture tests; however, these samples did not exhibit any infective microorganisms. Recently, on 31 March, 2017, the patient received her eleventh dosage of herceptin, without any evidence of infection. The patient's clinical course is summarized on Figure 1.

C Infection &

Chemotherapy

## DISCUSSION

R. aquatilis was first described in 1976 by Gavini and colleagues at Institut Pasteur. The name Rahnella is derived from the name of bacteriologist Otto Rahn, while "aquatilis" is derived from the Latin term for water [3]. The first clinical isolate of *R. aquatilis* was reported to the Center for Disease Control and Prevention in 1985 [4]. Most cases of R. aquatilis infection have been reported in compromised hosts or young children [5, 6]. A case of iatrogenic inoculation by contaminated intravenous fluid also been reported in a healthy adult [7]. The history of R. aquatilis since its discovery is relatively short; only a few pathological manifestations of the organism are understood, and it is confused with *Pantoea agalomerans* because of similarity in biochemical characteristics [8]. However, Rahnella does have a few characteristic traits and has now been included in commercial databases for easier detection in clinical and environmental samples. Currently, the VITEK, BBL Crystal ID, and API 20E systems include *R. aquatilis* in their databases, and identification of the organism is relatively easy [7]. To our knowledge, there are approximately 20 to 30 case reports of *R. aquatilis* infection in humans. Except for a few, most of these cases —including the present case— involve patients with diabetes mellitus, alcoholism, acquired immune deficiency syndrome, or cancer, which indicates that this organism might cause opportunistic infections. R. aquatilis has been isolated from blood, wound, urine, respiratory tract, and stool samples [5]. Although the origin of the *R. aquatilis* strain isolated from our patient is unclear, catheter related blood stream infection (CRBSI) was suspected clinically because fever and chill were developed in a patient with central venous catheter without any localizing sign [8]. Unfortunately, we could not get any definitive evidence of CRBSI. One possible reason is that appropriate blood culture – peripheral venous blood collection accompanied with central catheter blood



C Infection & Chemotherapy

## REFERENCES

- Alballaa SR, Qadri SM, al-Furayh O, al-Qatary K. Urinary tract infection due to *Rahnella aquatilis* in a renal transplant patient. J Clin Microbiol 1992;30:2948-50.
  PUBMED
- Song JH, Kim DI, Ahn IS, Cha YS, Ahn JH, Kang MS. Rahnella aquatilis bacteremia in a hemodialysis patient. Korean J Nephrol 1997;16:178-82.
- 3. Tash K. *Rahnella aquatilis* bacteremia from a suspected urinary source. J Clin Microbiol 2005;43:2526-8. PUBMED | CROSSREF
- Farmer JJ 3rd, Davis BR, Hickman-Brenner FW, McWhorter A, Huntley-Carter GP, Asbury MA, Riddle C, Wathen-Grady HG, Elias C, Fanning GR, Steigerwalt AG, O'hara CM, Morris GK, Smith PB, Brenner DJ. Biochemical identification of new species and biogroups of *Enterobacteriaceae* isolated from clinical specimens. J Clin Microbiol 1985;21:46-76.
- Kuzdan C, Soysal A, Özdemir H, Coşkun Ş, Akman I, Bilgen H, Özek E, Bakir M. Rahnella aquatilis sepsis in a premature newborn. Case Rep Pediatr 2015;2015:860671.
  PUBMED | CROSSREF
- Matsukura H, Katayama K, Kitano N, Kobayashi K, Kanegane C, Higuchi A, Kyotani S. Infective endocarditis caused by an unusual gram-negative rod, *Rahnella aquatilis*. Pediatr Cardiol 1996;17:108-11.
  PUBMED | CROSSREF
- Chang CL, Jeong J, Shin JH, Lee EY, Son HC. *Rahnella aquatilis* sepsis in an immunocompetent adult. J Clin Microbiol 1999;37:4161-2.
- Gahlot R, Nigam C, Kumar V, Yadav G, Anupurba S. Catheter-related bloodstream infections. Int J Crit Illn Inj Sci 2014;4:162-7.
  PUBMED | CROSSREF
- 9. Caroff N, Chamoux C, Le Gallou F, Espaze E, Gavini F, Gautreau D, Richet H, Reynaud A. Two epidemiologically related cases of *Rahnella aquatilis* bacteremia. Eur J Clin Microbiol Infect Dis 1998;17:349-52. PUBMED



- Maraki S, Samonis G, Marnelakis E, Tselentis Y. Surgical wound infection caused by *Rahnella aquatilis*. J Clin Microbiol 1994;32:2706-8.
- Stock I, Grüger T, Wiedemann B. Natural antibiotic susceptibility of *Rahnella aquatilis* and *R. aquatilis*related strains. J Chemother 2000;12:30-9.
- Goubau P, Van Aelst F, Verhaegen J, Boogaerts M. Septicaemia caused by *Rahnella aquatilis* in an immunocompromised patient. Eur J Clin Microbiol Infect Dis 1988;7:697-9.
  PUBMED | CROSSREF
- Hoppe JE, Herter M, Aleksic S, Klingebiel T, Niethammer D. Catheter-related *Rahnella aquatilis* bacteremia in a pediatric bone marrow transplant recipient. J Clin Microbiol 1993;31:1911-2.
  PUBMED
- Carinder JE, Chua JD, Corales RB, Taege AJ, Procop GW. *Rahnella aquatilis* bacteremia in a patient with relapsed acute lymphoblastic leukemia. Scand J Infect Dis 2001;33:471-3.
  PUBMED | CROSSREF
- Lee SW, Lee DK, An HM, Cha MK, Kim KJ, Ha NJ. Enteropathogenic bacteria contamination of unchlorinated drinking water in Korea, 2010. Environ Health Toxicol 2011;26:e2011016.
  PUBMED | CROSSREF